Home › Funds › Medicxi Ventures Management (Jersey) Ltd › NAMS
Medicxi Ventures Management (Jersey) Ltd position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
Medicxi Ventures Management (Jersey) Ltd reported holding 2,182,339 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$53.1M, representing 41.90% of its reported portfolio and ranking #2 among its reported holdings. Medicxi Ventures Management (Jersey) Ltd has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Medicxi Ventures Management (Jersey) Ltd's NAMS position evolved
Medicxi Ventures Management (Jersey) Ltd first disclosed a stake in NAMS in Q3 2023 at 2,869,565 shares (US$26.5M). The position peaked in Q4 2025 at 2,869,565 shares, worth US$100.7M. Across 13 filings, Medicxi Ventures Management (Jersey) Ltd increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 2,182,339 shares valued at US$53.1M — a reduction of -26,300 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.87M | $26.54M | New |
| Q4 2023 | 2.87M | $32.05M | Hold |
| Q1 2024 | 2.87M | $67.87M | Hold |
| Q2 2024 | 2.87M | $55.12M | Hold |
| Q3 2024 | 2.87M | $47.63M | Hold |
| Q4 2024 | 2.87M | $73.75M | Hold |
| Q1 2025 | 2.87M | $58.74M | Hold |
| Q2 2025 | 2.87M | $51.97M | Hold |
| Q3 2025 | 2.87M | $81.61M | Hold |
| Q4 2025 | 2.87M | $100.66M | Hold |
| Q1 2026 | 2.67M | $85.60M | Reduce |
| Q2 2026 | 2.21M | $74.85M | Reduce |
| Q3 2026 | 2.18M | $53.07M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 41 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.09M sh · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $323.66M · Q2 2026
- FCPM III SERVICES B.V. 8.49M sh · $287.74M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.26M sh · $144.53M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $129.00M · Q2 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M sh · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M sh · $104.05M · Q2 2026
- Castle Hook Partners LP 1.37M sh · $46.46M · Q2 2026
- NWI MANAGEMENT LP 702.00K sh · $23.79M · Q2 2026
- Rock Springs Capital Management LP 582.74K sh · $19.75M · Q2 2026
- First Turn Management, LLC 582.50K sh · $19.74M · Q2 2026
More on Medicxi Ventures Management (Jersey) Ltd
FAQ
How long has Medicxi Ventures Management (Jersey) Ltd held NAMS?
Medicxi Ventures Management (Jersey) Ltd has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Medicxi Ventures Management (Jersey) Ltd's current position in NAMS?
As of Q3 2026, Medicxi Ventures Management (Jersey) Ltd holds 2.18M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $53.07M, representing 41.90% of its reported portfolio and ranking #2.
Has Medicxi Ventures Management (Jersey) Ltd been buying or selling NAMS?
In the latest 13F filing (Q3 2026), Medicxi Ventures Management (Jersey) Ltd reduced its position in NAMS. The position peaked in Q4 2025 at 2.87M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.